Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G. Eliaschewitz, Denise Reis Franco, Ole Kleist Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D. Pedersen, Cees J. Tack, Mette S. Thomsen, Tina Vilsbøll, Mark Warren, Stephen C. Bain

New England Journal of Medicine, 2019

Ted Rogers Centre for Heart Research, Paul Langerhans Institute Dresden, Helmholtz Zentrum München, Technische Universität Dresden, German Center for Diabetes Research, Deutsches Diabetes-Zentrum e.V., King's College London, Heinrich Heine University Düsseldorf, King's College - North Carolina, Novo Nordisk (Denmark), The Ohio State University, DASA (Brazil), The University of Texas Southwestern Medical Center, Hebrew University of Jerusalem, LMC Diabetes & Endocrinology (Canada), Steno Diabetes Centers, University of Copenhagen, Physicians East, Swansea University

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1848

Citations

View on Google Scholar

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Abstract

Journal Details

Join JournalsHub

Welcome Back